Cardiovascular Toxicities Associated With Ibrutinib-Reference-Cited by-同舟云学术

Cardiovascular Toxicities Associated With Ibrutinib

Published:2019-10 Issue:13 Volume:74 Page:1667-1678
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Salem Joe-Elie,Manouchehri Ali,Bretagne Marie,Lebrun-Vignes Bénédicte,Groarke John D.,Johnson Douglas B.,Yang Tao,Reddy Nishitha M.,Funck-Brentano Christian,Brown Jennifer R.,Roden Dan M.,Moslehi Javid J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference56 articles.

1. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy;Miklos;Blood,2017

2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

3. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

4. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study;Dreyling;Lancet,2016

5. Ibrutinib in previously treated Waldenstrom's macroglobulinemia;Treon;N Engl J Med,2015

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pericardial events associated with ibrutinib‐based therapies for chronic lymphocytic leukaemia in two landmark trials;British Journal of Haematology;2024-09

2. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice;Blood Neoplasia;2024-09

3. Ibrutinib-Induced Ventricular Electrical Storm Successfully Managed with Veno-Arterial ECMO and Intralipid Administration: A Rare Case Report;Annals of Cardiac Anaesthesia;2024-08-28

4. Cancer and Heart Failure: Dangerous Liaisons;Journal of Cardiovascular Development and Disease;2024-08-27

5. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21